- Conditions
- Ovarian Neoplasms
- Interventions
- Niraparib, Bevacizumab
- Drug · Biological
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 29
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 1,396
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer
- Interventions
- carboplatin, cisplatin, docetaxel, fluorouracil
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 14
- States / cities
- La Jolla, California • Denver, Colorado • Boca Raton, Florida + 11 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 25
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Santa Monica, California + 21 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Pleural Mesothelioma, Malignant Pleural Mesothelioma
- Interventions
- Cisplatin, Sodium Thiosulfate, ALIMTA
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Cervical Cancer
- Interventions
- Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
- Drug · Radiation · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Small Cell Lung Cancer
- Interventions
- picoplatin
- Drug
- Lead sponsor
- Poniard Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 28
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • Palm Springs, California + 25 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- LY573636-sodium
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Platinum-Sensitive Ovarian Cancer, Ovarian Cancer
- Interventions
- Rina-S, Bevacizumab, Carboplatin, Gemcitabine, Paclitaxel, PLD
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Danbury, Connecticut • Waukesha, Wisconsin
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 10
- States / cities
- Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma
- Interventions
- Cytoreductive Surgery (CRS), Adjuvant Chemotherapy, Questionnaire, Hyperthermic intraperitoneal chemotherapy, Carboplatin, Paclitaxel, Cisplatin
- Procedure · Drug · Other
- Lead sponsor
- Mercy Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ovarian Neoplasms
- Interventions
- Niraparib, Placebo
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 47
- States / cities
- Tempe, Arizona • Tucson, Arizona • San Francisco, California + 41 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- Ramucirumab, Trastuzumab, Capecitabine, Cisplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
- Interventions
- Topotecan Hydrochloride Liposomes, 3-Dimensional Conformal Radiation Therapy, Cisplatin
- Drug · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Columbia, Missouri + 5 more
- Conditions
- Osteosarcoma, Lung Metastases
- Interventions
- Dexrazoxane, Doxorubicin, Cisplatin, G-CSF, PEG-filgrastim, Etoposide, Ifosfamide, Mesna, Leucovorin
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 2 Years to 35 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy
- Drug · Device
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
- Biological · Drug
- Lead sponsor
- Mural Oncology, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin, docetaxel, fluorouracil, computed tomography, positron emission tomography, quality-of-life assessment, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
- Biological · Procedure · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more